Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay
Identifieur interne : 00B639 ( Main/Exploration ); précédent : 00B638; suivant : 00B640Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay
Auteurs : Anna S. F. Lok [États-Unis] ; Fabien Zoulim [France] ; Stephen Locarnini [Australie] ; Alessandra Mangia [Italie] ; Grazia Niro [Italie] ; Hilde Decraemer [Belgique] ; Geert Maertens [Belgique] ; Frank Hulstaert [Belgique] ; Karen De Vreese [Belgique] ; Erwin Sablon [Belgique]Source :
- Journal of clinical microbiology [ 0095-1137 ] ; 2002.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Sensitive and early detection of emerging hepatitis B virus (HBV) drug resistance may not only help monitor the viral dynamics associated with lamivudine treatment but could also improve therapeutic decision making. This is especially important when new antivirals effective against lamivudine-resistant HBV become available. A total of 159 serum samples from 33 chronic HBV patients receiving lamivudine treatment were analyzed at four centers for the presence of lamivudine-resistant mutations at codons 528 [180] (proposed revised nomenclature according to Stuyver et al. [Hepatology 33:751-757, 2001] shown in brackets), 552 [204], and 555 [207] of the HBV polymerase. Sequencing data were compared with results generated by the INNO-LiPA HBV DR line probe assay (LiPA), an assay based on reverse hybridization of amplified HBV DNA fragments with specific nucleotide probes immobilized on nitrocellulose strips. LiPA provided at least the same information as sequencing for 97.5% of all codons analyzed for codon 528 [180], 95% for codon 552 [204], and 100% for codon 555 [207]. The most common reason for discrepant or indeterminate results (0.4% and 1.5%, respectively) in a small percentage of the population tested could be attributed to polymorphisms not yet covered by LiPA probes. In at least five patients, a mutant could be detected earlier by LiPA than by sequencing. In 15 patients, LiPA detected mixed wild-type and mutant virus populations before viral breakthrough. These results demonstrate that INNO-LiPA HBV DR is a highly sensitive and easily applicable assay for the detection and monitoring of lamivudine-resistant mutations in chronic hepatitis B patients and that the assay is more sensitive than sequencing in detecting mixed mutant and wild-type sequences.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 005420
- to stream PascalFrancis, to step Curation: 000D06
- to stream PascalFrancis, to step Checkpoint: 005326
- to stream Main, to step Merge: 00C447
- to stream Pmc, to step Corpus: 001014
- to stream Pmc, to step Curation: 000E75
- to stream Pmc, to step Checkpoint: 002D36
- to stream Ncbi, to step Merge: 000062
- to stream Ncbi, to step Curation: 000062
- to stream Ncbi, to step Checkpoint: 000062
- to stream Main, to step Merge: 00C123
- to stream Main, to step Curation: 00B639
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay</title><author><name sortKey="Lok, Anna S F" sort="Lok, Anna S F" uniqKey="Lok A" first="Anna S. F." last="Lok">Anna S. F. Lok</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Gastroenterology, University of Michigan Medical Center</s1><s2>Ann Arbor, Michigan 48109</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Ann Arbor, Michigan 48109</wicri:noRegion></affiliation></author><author><name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM Unit 271, Institut Universitaire de France</s1><s2>69003 Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>69003 Lyon</wicri:noRegion><placeName><settlement type="city">Lyon</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation></author><author><name sortKey="Locarnini, Stephen" sort="Locarnini, Stephen" uniqKey="Locarnini S" first="Stephen" last="Locarnini">Stephen Locarnini</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Research and Molecular Development, WHO Collaborating Centers for Virus Reference and Research and for Biosafety, The Victorian Infectious Diseases Reference Laboratory</s1><s2>North Melbourne 3051</s2><s3>AUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>North Melbourne 3051</wicri:noRegion></affiliation></author><author><name sortKey="Mangia, Alessandra" sort="Mangia, Alessandra" uniqKey="Mangia A" first="Alessandra" last="Mangia">Alessandra Mangia</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Divisione di Gastroenterologia, Ospedale Generale Regionale "Casa Sollievo della Sofferenza"</s1><s2>71013 San Giovanni Rotondo (Fg)</s2><s3>ITA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>71013 San Giovanni Rotondo (Fg)</wicri:noRegion></affiliation></author><author><name sortKey="Niro, Grazia" sort="Niro, Grazia" uniqKey="Niro G" first="Grazia" last="Niro">Grazia Niro</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Divisione di Gastroenterologia, Ospedale Generale Regionale "Casa Sollievo della Sofferenza"</s1><s2>71013 San Giovanni Rotondo (Fg)</s2><s3>ITA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>71013 San Giovanni Rotondo (Fg)</wicri:noRegion></affiliation></author><author><name sortKey="Decraemer, Hilde" sort="Decraemer, Hilde" uniqKey="Decraemer H" first="Hilde" last="Decraemer">Hilde Decraemer</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Innogenetics N. V.</s1><s2>9052 Ghent</s2><s3>BEL</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Innogenetics N. V.</wicri:noRegion></affiliation></author><author><name sortKey="Maertens, Geert" sort="Maertens, Geert" uniqKey="Maertens G" first="Geert" last="Maertens">Geert Maertens</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Innogenetics N. V.</s1><s2>9052 Ghent</s2><s3>BEL</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Innogenetics N. V.</wicri:noRegion></affiliation></author><author><name sortKey="Hulstaert, Frank" sort="Hulstaert, Frank" uniqKey="Hulstaert F" first="Frank" last="Hulstaert">Frank Hulstaert</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Innogenetics N. V.</s1><s2>9052 Ghent</s2><s3>BEL</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Innogenetics N. V.</wicri:noRegion></affiliation></author><author><name sortKey="De Vreese, Karen" sort="De Vreese, Karen" uniqKey="De Vreese K" first="Karen" last="De Vreese">Karen De Vreese</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Innogenetics N. V.</s1><s2>9052 Ghent</s2><s3>BEL</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Innogenetics N. V.</wicri:noRegion></affiliation></author><author><name sortKey="Sablon, Erwin" sort="Sablon, Erwin" uniqKey="Sablon E" first="Erwin" last="Sablon">Erwin Sablon</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Innogenetics N. V.</s1><s2>9052 Ghent</s2><s3>BEL</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Innogenetics N. V.</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">03-0159055</idno><date when="2002">2002</date><idno type="stanalyst">PASCAL 03-0159055 INIST</idno><idno type="RBID">Pascal:03-0159055</idno><idno type="wicri:Area/PascalFrancis/Corpus">005420</idno><idno type="wicri:Area/PascalFrancis/Curation">000D06</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">005326</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">005326</idno><idno type="wicri:doubleKey">0095-1137:2002:Lok A:monitoring:drug:resistance</idno><idno type="wicri:Area/Main/Merge">00C447</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC130856</idno><idno type="RBID">PMC:130856</idno><idno type="wicri:Area/Pmc/Corpus">001014</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001014</idno><idno type="wicri:Area/Pmc/Curation">000E75</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000E75</idno><idno type="wicri:Area/Pmc/Checkpoint">002D36</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002D36</idno><idno type="wicri:Area/Ncbi/Merge">000062</idno><idno type="wicri:Area/Ncbi/Curation">000062</idno><idno type="wicri:Area/Ncbi/Checkpoint">000062</idno><idno type="wicri:doubleKey">0095-1137:2002:Lok A:monitoring:drug:resistance</idno><idno type="wicri:Area/Main/Merge">00C123</idno><idno type="wicri:Area/Main/Curation">00B639</idno><idno type="wicri:Area/Main/Exploration">00B639</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay</title><author><name sortKey="Lok, Anna S F" sort="Lok, Anna S F" uniqKey="Lok A" first="Anna S. F." last="Lok">Anna S. F. Lok</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Gastroenterology, University of Michigan Medical Center</s1><s2>Ann Arbor, Michigan 48109</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Ann Arbor, Michigan 48109</wicri:noRegion></affiliation></author><author><name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM Unit 271, Institut Universitaire de France</s1><s2>69003 Lyon</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>69003 Lyon</wicri:noRegion><placeName><settlement type="city">Lyon</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region></placeName></affiliation></author><author><name sortKey="Locarnini, Stephen" sort="Locarnini, Stephen" uniqKey="Locarnini S" first="Stephen" last="Locarnini">Stephen Locarnini</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Research and Molecular Development, WHO Collaborating Centers for Virus Reference and Research and for Biosafety, The Victorian Infectious Diseases Reference Laboratory</s1><s2>North Melbourne 3051</s2><s3>AUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>North Melbourne 3051</wicri:noRegion></affiliation></author><author><name sortKey="Mangia, Alessandra" sort="Mangia, Alessandra" uniqKey="Mangia A" first="Alessandra" last="Mangia">Alessandra Mangia</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Divisione di Gastroenterologia, Ospedale Generale Regionale "Casa Sollievo della Sofferenza"</s1><s2>71013 San Giovanni Rotondo (Fg)</s2><s3>ITA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>71013 San Giovanni Rotondo (Fg)</wicri:noRegion></affiliation></author><author><name sortKey="Niro, Grazia" sort="Niro, Grazia" uniqKey="Niro G" first="Grazia" last="Niro">Grazia Niro</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Divisione di Gastroenterologia, Ospedale Generale Regionale "Casa Sollievo della Sofferenza"</s1><s2>71013 San Giovanni Rotondo (Fg)</s2><s3>ITA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>71013 San Giovanni Rotondo (Fg)</wicri:noRegion></affiliation></author><author><name sortKey="Decraemer, Hilde" sort="Decraemer, Hilde" uniqKey="Decraemer H" first="Hilde" last="Decraemer">Hilde Decraemer</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Innogenetics N. V.</s1><s2>9052 Ghent</s2><s3>BEL</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Innogenetics N. V.</wicri:noRegion></affiliation></author><author><name sortKey="Maertens, Geert" sort="Maertens, Geert" uniqKey="Maertens G" first="Geert" last="Maertens">Geert Maertens</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Innogenetics N. V.</s1><s2>9052 Ghent</s2><s3>BEL</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Innogenetics N. V.</wicri:noRegion></affiliation></author><author><name sortKey="Hulstaert, Frank" sort="Hulstaert, Frank" uniqKey="Hulstaert F" first="Frank" last="Hulstaert">Frank Hulstaert</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Innogenetics N. V.</s1><s2>9052 Ghent</s2><s3>BEL</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Innogenetics N. V.</wicri:noRegion></affiliation></author><author><name sortKey="De Vreese, Karen" sort="De Vreese, Karen" uniqKey="De Vreese K" first="Karen" last="De Vreese">Karen De Vreese</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Innogenetics N. V.</s1><s2>9052 Ghent</s2><s3>BEL</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Innogenetics N. V.</wicri:noRegion></affiliation></author><author><name sortKey="Sablon, Erwin" sort="Sablon, Erwin" uniqKey="Sablon E" first="Erwin" last="Sablon">Erwin Sablon</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Innogenetics N. V.</s1><s2>9052 Ghent</s2><s3>BEL</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Innogenetics N. V.</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Journal of clinical microbiology</title><title level="j" type="abbreviated">J. clin. microbiol.</title><idno type="ISSN">0095-1137</idno><imprint><date when="2002">2002</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of clinical microbiology</title><title level="j" type="abbreviated">J. clin. microbiol.</title><idno type="ISSN">0095-1137</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term><term>Chronic</term><term>Dideoxynucleoside</term><term>Enzyme inhibitor</term><term>Hepatitis B virus</term><term>Human</term><term>Lamivudine</term><term>Nucleosidic analog</term><term>Performance evaluation</term><term>Pyrimidine nucleoside</term><term>RNA-directed DNA polymerase</term><term>Resistance</term><term>Reverse transcriptase inhibitor</term><term>Treatment</term><term>Viral hepatitis B</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Virus hépatite B</term><term>Homme</term><term>Résistance</term><term>Lamivudine</term><term>Traitement</term><term>Evaluation performance</term><term>Chronique</term><term>Hépatite virale B</term><term>Antiviral</term><term>Analogue nucléoside</term><term>Didésoxynucléoside</term><term>Inhibiteur enzyme</term><term>Inhibiteur reverse transcriptase</term><term>Pyrimidine nucléoside</term><term>RNA-directed DNA polymerase</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sensitive and early detection of emerging hepatitis B virus (HBV) drug resistance may not only help monitor the viral dynamics associated with lamivudine treatment but could also improve therapeutic decision making. This is especially important when new antivirals effective against lamivudine-resistant HBV become available. A total of 159 serum samples from 33 chronic HBV patients receiving lamivudine treatment were analyzed at four centers for the presence of lamivudine-resistant mutations at codons 528 [180] (proposed revised nomenclature according to Stuyver et al. [Hepatology 33:751-757, 2001] shown in brackets), 552 [204], and 555 [207] of the HBV polymerase. Sequencing data were compared with results generated by the INNO-LiPA HBV DR line probe assay (LiPA), an assay based on reverse hybridization of amplified HBV DNA fragments with specific nucleotide probes immobilized on nitrocellulose strips. LiPA provided at least the same information as sequencing for 97.5% of all codons analyzed for codon 528 [180], 95% for codon 552 [204], and 100% for codon 555 [207]. The most common reason for discrepant or indeterminate results (0.4% and 1.5%, respectively) in a small percentage of the population tested could be attributed to polymorphisms not yet covered by LiPA probes. In at least five patients, a mutant could be detected earlier by LiPA than by sequencing. In 15 patients, LiPA detected mixed wild-type and mutant virus populations before viral breakthrough. These results demonstrate that INNO-LiPA HBV DR is a highly sensitive and easily applicable assay for the detection and monitoring of lamivudine-resistant mutations in chronic hepatitis B patients and that the assay is more sensitive than sequencing in detecting mixed mutant and wild-type sequences.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>France</li><li>Italie</li><li>États-Unis</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li></settlement></list><tree><country name="États-Unis"><noRegion><name sortKey="Lok, Anna S F" sort="Lok, Anna S F" uniqKey="Lok A" first="Anna S. F." last="Lok">Anna S. F. Lok</name></noRegion></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name></region></country><country name="Australie"><noRegion><name sortKey="Locarnini, Stephen" sort="Locarnini, Stephen" uniqKey="Locarnini S" first="Stephen" last="Locarnini">Stephen Locarnini</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Mangia, Alessandra" sort="Mangia, Alessandra" uniqKey="Mangia A" first="Alessandra" last="Mangia">Alessandra Mangia</name></noRegion><name sortKey="Niro, Grazia" sort="Niro, Grazia" uniqKey="Niro G" first="Grazia" last="Niro">Grazia Niro</name></country><country name="Belgique"><noRegion><name sortKey="Decraemer, Hilde" sort="Decraemer, Hilde" uniqKey="Decraemer H" first="Hilde" last="Decraemer">Hilde Decraemer</name></noRegion><name sortKey="De Vreese, Karen" sort="De Vreese, Karen" uniqKey="De Vreese K" first="Karen" last="De Vreese">Karen De Vreese</name><name sortKey="Hulstaert, Frank" sort="Hulstaert, Frank" uniqKey="Hulstaert F" first="Frank" last="Hulstaert">Frank Hulstaert</name><name sortKey="Maertens, Geert" sort="Maertens, Geert" uniqKey="Maertens G" first="Geert" last="Maertens">Geert Maertens</name><name sortKey="Sablon, Erwin" sort="Sablon, Erwin" uniqKey="Sablon E" first="Erwin" last="Sablon">Erwin Sablon</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00B639 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00B639 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:03-0159055
|texte= Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay
}}
| This area was generated with Dilib version V0.6.33. |  |